Report cover image

Global Therapeutic Radioligands Drug Market by Size, by Type, by Application, by Region, History and Forecast 2020-2031

Publisher APO Research, Inc.
Published Jul 08, 2025
Length 197 Pages
SKU # APRC20278148

Description

Summary

According to APO Research, The global Therapeutic Radioligands Drug market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Therapeutic Radioligands Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Therapeutic Radioligands Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Therapeutic Radioligands Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Therapeutic Radioligands Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global companies of Therapeutic Radioligands Drug include Novartis, Mundipharma, Bayer, Y-mAbs Therapeutics, Telix Pharmaceuticals, RadioMedix, Philogen, Orano Med and Nordic Nanovector, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Therapeutic Radioligands Drug, market size. Analyses of the global market trends, with historic market revenue data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Therapeutic Radioligands Drug, also provides the revenue of main regions and countries. Of the upcoming market potential for Therapeutic Radioligands Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Therapeutic Radioligands Drug revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Therapeutic Radioligands Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2020 to 2031. Evaluation and forecast the market size for Therapeutic Radioligands Drug revenue, projected growth trends, production technology, application and end-user industry.

Therapeutic Radioligands Drug Segment by Company

Novartis
Mundipharma
Bayer
Y-mAbs Therapeutics
Telix Pharmaceuticals
RadioMedix
Philogen
Orano Med
Nordic Nanovector
Lantheus
Gilead Sciences
Fusion Pharmaceuticals
Curium Pharmaceuticals
Curasight
Clarity Pharmaceuticals
China Isotope & Radiation
Aurobindo Pharma
Actinium Pharmaceuticals
Therapeutic Radioligands Drug Segment by Type

Beta-emitting
Targeted Alpha Therapy
Therapeutic Radioligands Drug Segment by Application

Solid Tumor
Non Hodgkin Lymphoma
Therapeutic Radioligands Drug Segment by Region

North America

United States
Canada
Mexico
Europe

Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific

China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America

Brazil
Argentina
Chile
Middle East & Africa

Egypt
South Africa
Israel
Türkiye
GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Therapeutic Radioligands Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Therapeutic Radioligands Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Therapeutic Radioligands Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Therapeutic Radioligands Drug in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Therapeutic Radioligands Drug industry.
Chapter 3: Detailed analysis of Therapeutic Radioligands Drug companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Therapeutic Radioligands Drugrevenue, gross margin, and recent development, etc.
Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 8: Europe by type, by application and by country, revenue for each segment.
Chapter 9: China by type, and by application, revenue for each segment.
Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.
Chapter 12: Concluding Insights of the report.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

197 Pages
1 Market Overview
1.1 Product Definition
1.2 Market Analysis by Type
1.2.1 Global Therapeutic Radioligands Drug Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Beta-emitting
1.2.3 Targeted Alpha Therapy
1.3 Market Analysis by Application
1.3.1 Global Therapeutic Radioligands Drug Market Size Growth Rate by Application: 2020 VS 2024 VS 2031
1.3.2 Solid Tumor
1.3.3 Non Hodgkin Lymphoma
1.4 Global Market Growth Prospects
1.5 Global Therapeutic Radioligands Drug Growth Trends by Region
1.5.1 Global Therapeutic Radioligands Drug Market Size by Region: 2020 VS 2024 VS 2031
1.5.2 Therapeutic Radioligands Drug Market Size by Region (2020-2025)
1.5.3 Therapeutic Radioligands Drug Market Size by Region (2026-2031)
1.6 Assumptions and Limitations
1.7 Study Goals and Objectives
1.8 Years Considered
2 Global Therapeutic Radioligands Drug Market Dynamics
2.1 Therapeutic Radioligands Drug Industry Trends
2.2 Therapeutic Radioligands Drug Industry Drivers
2.3 Therapeutic Radioligands Drug Industry Opportunities and Challenges
2.4 Therapeutic Radioligands Drug Industry Restraints
3 Competitive Landscape by Company
3.1 Global Therapeutic Radioligands Drug Revenue by Company (2020-2025)
3.2 Global Therapeutic Radioligands Drug Players Revenue Ranking, 2023 VS 2024 VS 2025
3.3 Global Therapeutic Radioligands Drug Key Company Head office and Area Served
3.4 Global Therapeutic Radioligands Drug Company, Product Type & Application
3.5 Global Therapeutic Radioligands Drug Company Establishment Date
3.6 Market Competitive Analysis
3.6.1 Global Therapeutic Radioligands Drug Market CR5 and HHI
3.6.2 Global Top 5 and 10 Therapeutic Radioligands Drug Players Market Share by Revenue in 2024
3.6.3 2024 Therapeutic Radioligands Drug Tier 1, Tier 2, and Tier 3
4 Therapeutic Radioligands Drug Market by Type
4.1 Global Therapeutic Radioligands Drug Market Size by Type (2020 VS 2024 VS 2031)
4.2 Global Therapeutic Radioligands Drug Market Size by Type (2020-2031)
4.3 Global Therapeutic Radioligands Drug Market Size Share by Type (2020-2031)
5 Therapeutic Radioligands Drug Market by Application
5.1 Global Therapeutic Radioligands Drug Market Size by Application (2020 VS 2024 VS 2031)
5.2 Global Therapeutic Radioligands Drug Market Size by Application (2020-2031)
5.3 Global Therapeutic Radioligands Drug Market Size Share by Application (2020-2031)
6 Company Profiles
6.1 Novartis
6.1.1 Novartis Comapny Information
6.1.2 Novartis Business Overview
6.1.3 Novartis Therapeutic Radioligands Drug Revenue and Gross Margin (US$ Million) & (2020-2025)
6.1.4 Novartis Therapeutic Radioligands Drug Product Portfolio
6.1.5 Novartis Recent Developments
6.2 Mundipharma
6.2.1 Mundipharma Comapny Information
6.2.2 Mundipharma Business Overview
6.2.3 Mundipharma Therapeutic Radioligands Drug Revenue and Gross Margin (US$ Million) & (2020-2025)
6.2.4 Mundipharma Therapeutic Radioligands Drug Product Portfolio
6.2.5 Mundipharma Recent Developments
6.3 Bayer
6.3.1 Bayer Comapny Information
6.3.2 Bayer Business Overview
6.3.3 Bayer Therapeutic Radioligands Drug Revenue and Gross Margin (US$ Million) & (2020-2025)
6.3.4 Bayer Therapeutic Radioligands Drug Product Portfolio
6.3.5 Bayer Recent Developments
6.4 Y-mAbs Therapeutics
6.4.1 Y-mAbs Therapeutics Comapny Information
6.4.2 Y-mAbs Therapeutics Business Overview
6.4.3 Y-mAbs Therapeutics Therapeutic Radioligands Drug Revenue and Gross Margin (US$ Million) & (2020-2025)
6.4.4 Y-mAbs Therapeutics Therapeutic Radioligands Drug Product Portfolio
6.4.5 Y-mAbs Therapeutics Recent Developments
6.5 Telix Pharmaceuticals
6.5.1 Telix Pharmaceuticals Comapny Information
6.5.2 Telix Pharmaceuticals Business Overview
6.5.3 Telix Pharmaceuticals Therapeutic Radioligands Drug Revenue and Gross Margin (US$ Million) & (2020-2025)
6.5.4 Telix Pharmaceuticals Therapeutic Radioligands Drug Product Portfolio
6.5.5 Telix Pharmaceuticals Recent Developments
6.6 RadioMedix
6.6.1 RadioMedix Comapny Information
6.6.2 RadioMedix Business Overview
6.6.3 RadioMedix Therapeutic Radioligands Drug Revenue and Gross Margin (US$ Million) & (2020-2025)
6.6.4 RadioMedix Therapeutic Radioligands Drug Product Portfolio
6.6.5 RadioMedix Recent Developments
6.7 Philogen
6.7.1 Philogen Comapny Information
6.7.2 Philogen Business Overview
6.7.3 Philogen Therapeutic Radioligands Drug Revenue and Gross Margin (US$ Million) & (2020-2025)
6.7.4 Philogen Therapeutic Radioligands Drug Product Portfolio
6.7.5 Philogen Recent Developments
6.8 Orano Med
6.8.1 Orano Med Comapny Information
6.8.2 Orano Med Business Overview
6.8.3 Orano Med Therapeutic Radioligands Drug Revenue and Gross Margin (US$ Million) & (2020-2025)
6.8.4 Orano Med Therapeutic Radioligands Drug Product Portfolio
6.8.5 Orano Med Recent Developments
6.9 Nordic Nanovector
6.9.1 Nordic Nanovector Comapny Information
6.9.2 Nordic Nanovector Business Overview
6.9.3 Nordic Nanovector Therapeutic Radioligands Drug Revenue and Gross Margin (US$ Million) & (2020-2025)
6.9.4 Nordic Nanovector Therapeutic Radioligands Drug Product Portfolio
6.9.5 Nordic Nanovector Recent Developments
6.10 Lantheus
6.10.1 Lantheus Comapny Information
6.10.2 Lantheus Business Overview
6.10.3 Lantheus Therapeutic Radioligands Drug Revenue and Gross Margin (US$ Million) & (2020-2025)
6.10.4 Lantheus Therapeutic Radioligands Drug Product Portfolio
6.10.5 Lantheus Recent Developments
6.11 Gilead Sciences
6.11.1 Gilead Sciences Comapny Information
6.11.2 Gilead Sciences Business Overview
6.11.3 Gilead Sciences Therapeutic Radioligands Drug Revenue and Gross Margin (US$ Million) & (2020-2025)
6.11.4 Gilead Sciences Therapeutic Radioligands Drug Product Portfolio
6.11.5 Gilead Sciences Recent Developments
6.12 Fusion Pharmaceuticals
6.12.1 Fusion Pharmaceuticals Comapny Information
6.12.2 Fusion Pharmaceuticals Business Overview
6.12.3 Fusion Pharmaceuticals Therapeutic Radioligands Drug Revenue and Gross Margin (US$ Million) & (2020-2025)
6.12.4 Fusion Pharmaceuticals Therapeutic Radioligands Drug Product Portfolio
6.12.5 Fusion Pharmaceuticals Recent Developments
6.13 Curium Pharmaceuticals
6.13.1 Curium Pharmaceuticals Comapny Information
6.13.2 Curium Pharmaceuticals Business Overview
6.13.3 Curium Pharmaceuticals Therapeutic Radioligands Drug Revenue and Gross Margin (US$ Million) & (2020-2025)
6.13.4 Curium Pharmaceuticals Therapeutic Radioligands Drug Product Portfolio
6.13.5 Curium Pharmaceuticals Recent Developments
6.14 Curasight
6.14.1 Curasight Comapny Information
6.14.2 Curasight Business Overview
6.14.3 Curasight Therapeutic Radioligands Drug Revenue and Gross Margin (US$ Million) & (2020-2025)
6.14.4 Curasight Therapeutic Radioligands Drug Product Portfolio
6.14.5 Curasight Recent Developments
6.15 Clarity Pharmaceuticals
6.15.1 Clarity Pharmaceuticals Comapny Information
6.15.2 Clarity Pharmaceuticals Business Overview
6.15.3 Clarity Pharmaceuticals Therapeutic Radioligands Drug Revenue and Gross Margin (US$ Million) & (2020-2025)
6.15.4 Clarity Pharmaceuticals Therapeutic Radioligands Drug Product Portfolio
6.15.5 Clarity Pharmaceuticals Recent Developments
6.16 China Isotope & Radiation
6.16.1 China Isotope & Radiation Comapny Information
6.16.2 China Isotope & Radiation Business Overview
6.16.3 China Isotope & Radiation Therapeutic Radioligands Drug Revenue and Gross Margin (US$ Million) & (2020-2025)
6.16.4 China Isotope & Radiation Therapeutic Radioligands Drug Product Portfolio
6.16.5 China Isotope & Radiation Recent Developments
6.17 Aurobindo Pharma
6.17.1 Aurobindo Pharma Comapny Information
6.17.2 Aurobindo Pharma Business Overview
6.17.3 Aurobindo Pharma Therapeutic Radioligands Drug Revenue and Gross Margin (US$ Million) & (2020-2025)
6.17.4 Aurobindo Pharma Therapeutic Radioligands Drug Product Portfolio
6.17.5 Aurobindo Pharma Recent Developments
6.18 Actinium Pharmaceuticals
6.18.1 Actinium Pharmaceuticals Comapny Information
6.18.2 Actinium Pharmaceuticals Business Overview
6.18.3 Actinium Pharmaceuticals Therapeutic Radioligands Drug Revenue and Gross Margin (US$ Million) & (2020-2025)
6.18.4 Actinium Pharmaceuticals Therapeutic Radioligands Drug Product Portfolio
6.18.5 Actinium Pharmaceuticals Recent Developments
7 North America
7.1 North America Therapeutic Radioligands Drug Market Size (2020-2031)
7.2 North America Therapeutic Radioligands Drug Market Size by Type
7.2.1 North America Therapeutic Radioligands Drug Market Size by Type (2020-2025)
7.2.2 North America Therapeutic Radioligands Drug Market Size by Type (2026-2031)
7.2.3 North America Therapeutic Radioligands Drug Market Share by Type (2020-2031)
7.3 North America Therapeutic Radioligands Drug Market Size by Application
7.3.1 North America Therapeutic Radioligands Drug Market Size by Application (2020-2025)
7.3.2 North America Therapeutic Radioligands Drug Market Size by Application (2026-2031)
7.3.3 North America Therapeutic Radioligands Drug Market Share by Application (2020-2031)
7.4 North America Therapeutic Radioligands Drug Market Size by Country
7.4.1 North America Therapeutic Radioligands Drug Market Size by Country (2020 VS 2024 VS 2031)
7.4.2 North America Therapeutic Radioligands Drug Market Size by Country (2020-2025)
7.4.3 North America Therapeutic Radioligands Drug Market Size by Country (2026-2031)
7.4.4 North America Therapeutic Radioligands Drug Market Share by Country (2020-2031)
7.4.5 United States
7.4.6 Canada
7.4.7 Mexico
8 Europe
8.1 Europe Therapeutic Radioligands Drug Market Size (2020-2031)
8.2 Europe Therapeutic Radioligands Drug Market Size by Type
8.2.1 Europe Therapeutic Radioligands Drug Market Size by Type (2020-2025)
8.2.2 Europe Therapeutic Radioligands Drug Market Size by Type (2026-2031)
8.2.3 Europe Therapeutic Radioligands Drug Market Share by Type (2020-2031)
8.3 Europe Therapeutic Radioligands Drug Market Size by Application
8.3.1 Europe Therapeutic Radioligands Drug Market Size by Application (2020-2025)
8.3.2 Europe Therapeutic Radioligands Drug Market Size by Application (2026-2031)
8.3.3 Europe Therapeutic Radioligands Drug Market Share by Application (2020-2031)
8.4 Europe Therapeutic Radioligands Drug Market Size by Country
8.4.1 Europe Therapeutic Radioligands Drug Market Size by Country (2020 VS 2024 VS 2031)
8.4.2 Europe Therapeutic Radioligands Drug Market Size by Country (2020-2025)
8.4.3 Europe Therapeutic Radioligands Drug Market Size by Country (2026-2031)
8.4.4 Europe Therapeutic Radioligands Drug Market Share by Country (2020-2031)
8.4.5 Germany
8.4.6 France
8.4.7 U.K.
8.4.8 Italy
8.4.9 Russia
8.4.10 Nordic Countries
9 China
9.1 China Therapeutic Radioligands Drug Market Size (2020-2031)
9.2 China Therapeutic Radioligands Drug Market Size by Type
9.2.1 China Therapeutic Radioligands Drug Market Size by Type (2020-2025)
9.2.2 China Therapeutic Radioligands Drug Market Size by Type (2026-2031)
9.2.3 China Therapeutic Radioligands Drug Market Share by Type (2020-2031)
9.3 China Therapeutic Radioligands Drug Market Size by Application
9.3.1 China Therapeutic Radioligands Drug Market Size by Application (2020-2025)
9.3.2 China Therapeutic Radioligands Drug Market Size by Application (2026-2031)
9.3.3 China Therapeutic Radioligands Drug Market Share by Application (2020-2031)
10 Asia (Excluding China)
10.1 Asia Therapeutic Radioligands Drug Market Size (2020-2031)
10.2 Asia Therapeutic Radioligands Drug Market Size by Type
10.2.1 Asia Therapeutic Radioligands Drug Market Size by Type (2020-2025)
10.2.2 Asia Therapeutic Radioligands Drug Market Size by Type (2026-2031)
10.2.3 Asia Therapeutic Radioligands Drug Market Share by Type (2020-2031)
10.3 Asia Therapeutic Radioligands Drug Market Size by Application
10.3.1 Asia Therapeutic Radioligands Drug Market Size by Application (2020-2025)
10.3.2 Asia Therapeutic Radioligands Drug Market Size by Application (2026-2031)
10.3.3 Asia Therapeutic Radioligands Drug Market Share by Application (2020-2031)
10.4 Asia Therapeutic Radioligands Drug Market Size by Country
10.4.1 Asia Therapeutic Radioligands Drug Market Size by Country (2020 VS 2024 VS 2031)
10.4.2 Asia Therapeutic Radioligands Drug Market Size by Country (2020-2025)
10.4.3 Asia Therapeutic Radioligands Drug Market Size by Country (2026-2031)
10.4.4 Asia Therapeutic Radioligands Drug Market Share by Country (2020-2031)
10.4.5 Japan
10.4.6 South Korea
10.4.7 Taiwan
10.4.8 Southeast Asia
10.4.9 India
10.4.10 Australia
11 South America, Middle East & Africa
11.1 South America, Middle East & Africa Therapeutic Radioligands Drug Market Size (2020-2031)
11.2 South America, Middle East & Africa Therapeutic Radioligands Drug Market Size by Type
11.2.1 South America, Middle East & Africa Therapeutic Radioligands Drug Market Size by Type (2020-2025)
11.2.2 South America, Middle East & Africa Therapeutic Radioligands Drug Market Size by Type (2026-2031)
11.2.3 South America, Middle East & Africa Therapeutic Radioligands Drug Market Share by Type (2020-2031)
11.3 South America, Middle East & Africa Therapeutic Radioligands Drug Market Size by Application
11.3.1 South America, Middle East & Africa Therapeutic Radioligands Drug Market Size by Application (2020-2025)
11.3.2 South America, Middle East & Africa Therapeutic Radioligands Drug Market Size by Application (2026-2031)
11.3.3 South America, Middle East & Africa Therapeutic Radioligands Drug Market Share by Application (2020-2031)
11.4 South America, Middle East & Africa Therapeutic Radioligands Drug Market Size by Country
11.4.1 South America, Middle East & Africa Therapeutic Radioligands Drug Market Size by Country (2020 VS 2024 VS 2031)
11.4.2 South America, Middle East & Africa Therapeutic Radioligands Drug Market Size by Country (2020-2025)
11.4.3 South America, Middle East & Africa Therapeutic Radioligands Drug Market Size by Country (2026-2031)
11.4.4 South America, Middle East & Africa Therapeutic Radioligands Drug Market Share by Country (2020-2031)
11.4.5 Brazil
11.4.6 South Africa
11.4.7 Saudi Arabia
11.4.8 Turkey
11.4.9 Argentina
11.4.9 UAE
11.4.9 Egypt
11.4.9 Chile
12 Concluding Insights
13 Appendix
13.1 Reasons for Doing This Study
13.2 Research Methodology
13.3 Research Process
13.4 Authors List of This Report
13.5 Data Source
13.5.1 Secondary Sources
13.5.2 Primary Sources
13.6 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.